FI3843723T3 - Helicobacter pylorin hävittämiseen tarkoitettu koostumus - Google Patents

Helicobacter pylorin hävittämiseen tarkoitettu koostumus

Info

Publication number
FI3843723T3
FI3843723T3 FIEP19855537.7T FI19855537T FI3843723T3 FI 3843723 T3 FI3843723 T3 FI 3843723T3 FI 19855537 T FI19855537 T FI 19855537T FI 3843723 T3 FI3843723 T3 FI 3843723T3
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salts
helicobacter pylori
use according
Prior art date
Application number
FIEP19855537.7T
Other languages
English (en)
Finnish (fi)
Inventor
Bong Tae Kim
Dongkyu Kim
Eun Ji Kim
Ji Won Lee
Kyeongmin Oh
Ahrong Kim
Geun Seog Song
Shin-Young Ryu
Eun Kyung Kim
Naree Shin
Hyun Ji Kang
Jae Min Kim
Yu-Gyeong Park
Haneul Jeong
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Application granted granted Critical
Publication of FI3843723T3 publication Critical patent/FI3843723T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FIEP19855537.7T 2018-08-29 2019-08-28 Helicobacter pylorin hävittämiseen tarkoitettu koostumus FI3843723T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (1)

Publication Number Publication Date
FI3843723T3 true FI3843723T3 (fi) 2026-02-12

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19855537.7T FI3843723T3 (fi) 2018-08-29 2019-08-28 Helicobacter pylorin hävittämiseen tarkoitettu koostumus

Country Status (27)

Country Link
US (2) US20210196685A1 (enExample)
EP (1) EP3843723B1 (enExample)
JP (1) JP7189327B2 (enExample)
KR (1) KR20200026118A (enExample)
CN (1) CN112638378A (enExample)
AR (1) AR116026A1 (enExample)
AU (1) AU2019328903B2 (enExample)
CA (1) CA3107624C (enExample)
DK (1) DK3843723T3 (enExample)
EA (1) EA202190622A1 (enExample)
ES (1) ES3060114T3 (enExample)
FI (1) FI3843723T3 (enExample)
GE (2) GEP20227431B (enExample)
HR (1) HRP20260170T1 (enExample)
JO (1) JOP20190201B1 (enExample)
LT (1) LT3843723T (enExample)
MX (1) MX2021002278A (enExample)
MY (1) MY195494A (enExample)
PH (1) PH12021550385A1 (enExample)
PT (1) PT3843723T (enExample)
RS (1) RS67791B1 (enExample)
SG (1) SG11202101920WA (enExample)
SI (1) SI3843723T1 (enExample)
SM (1) SMT202600153T1 (enExample)
UA (1) UA126993C2 (enExample)
UY (1) UY38348A (enExample)
WO (1) WO2020045992A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3955927A4 (en) * 2019-04-18 2023-06-07 Thomas Julius Borody COMPOSITIONS AND METHODS FOR TREATING, AMOUNTING AND PREVENTING H. PYLORI INFECTIONS
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
BR122020004679B1 (pt) 2005-12-19 2021-09-21 Raqualia Pharma Inc Composição farmacêutica
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
RU2672248C1 (ru) * 2015-06-08 2018-11-13 СиДжей ХЕЛТКЕР КОРПОРЕЙШН Применение производного бензимидазола для лечения ночного кислотного прорыва
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
EP3843723A4 (en) 2022-06-29
AU2019328903A1 (en) 2021-04-29
JP2021535910A (ja) 2021-12-23
AU2019328903B2 (en) 2023-01-05
SG11202101920WA (en) 2021-04-29
HRP20260170T1 (hr) 2026-05-08
UA126993C2 (uk) 2023-03-01
CN112638378A (zh) 2021-04-09
PH12021550385A1 (en) 2021-09-20
BR112021003578A2 (pt) 2021-05-18
EP3843723B1 (en) 2026-01-07
LT3843723T (lt) 2026-03-25
EP3843723A1 (en) 2021-07-07
GEAP202215593A (en) 2022-07-11
GEP20227431B (en) 2022-10-25
DK3843723T3 (da) 2026-02-09
US20210196685A1 (en) 2021-07-01
RS67791B1 (sr) 2026-03-31
CA3107624A1 (en) 2020-03-05
SMT202600153T1 (it) 2026-05-12
MX2021002278A (es) 2021-08-11
ES3060114T3 (enExample) 2026-03-25
CA3107624C (en) 2023-10-03
PT3843723T (pt) 2026-01-27
JOP20190201B1 (ar) 2024-04-18
WO2020045992A1 (en) 2020-03-05
US20250241897A1 (en) 2025-07-31
EA202190622A1 (ru) 2021-06-10
AU2019328903A8 (en) 2021-05-27
SI3843723T1 (sl) 2026-04-30
JP7189327B2 (ja) 2022-12-13
KR20200026118A (ko) 2020-03-10
MY195494A (en) 2023-01-26
AR116026A1 (es) 2021-03-25
JOP20190201A1 (ar) 2020-02-29
UY38348A (es) 2020-03-31

Similar Documents

Publication Publication Date Title
BRPI0508833A (pt) formulações galênicas de compostos orgánicos
SI2600851T1 (en) PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT
BRPI0518266A8 (pt) Medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
WO2011047173A3 (en) Pharmaceutical compositions for oral administration
IL314009B1 (en) Parp1 inhibitors and uses thereof
Niu et al. Esculentic acid, a novel and selective COX-2 inhibitor with anti-inflammatory effect in vivo and in vitro
EA201391018A1 (ru) Препараты иммуносупрессантов
PL210463B1 (pl) Zastosowanie kombinacji roflumilastu z diklofenakiem w leczeniu zapalnych chorób stawów
WO2023246870A9 (zh) 吲哚化合物的制备、应用及用途
BR112012003149B8 (pt) composição farmacêutica para alívio de dor em uma doença de junta humana
KR20100100584A (ko) 장질환 치료용 이소소르비드 모노니트레이트 유도체
BR112022004099A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
ES2390226T3 (es) Tratamiento de enfermedades infecciosas
MX2022016497A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica.
BR112022009533A2 (pt) Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
JP2008088189A5 (enExample)
US20060074079A1 (en) Solid pharmaceutical formulations comprising Diacereine and Meloxicam
WO2017209588A3 (fr) Formulation pharmaceutique de cinéol et d'amoxicilline
CR20190203A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
ES2365387T3 (es) Composiciones analgésicas y antiflamatorias que contienen celecoxib e ibuprofeno.
CL2008001411A1 (es) Composicion farmaceutica que comprende al menos una fase interna no lipoidea y al menos una fase externa lipoidea que es bioadhesiva a una superficie de la mucosa vaginal y que comprende danazol de 1 a 30% en peso; procedimiento de preparacion; sistema de administracion; y uso para tratar afecciones inflamatorias
RU2684783C1 (ru) Композиция антиоксидантов, пригодная для перорального применения в терапии воспалительного процесса в легких
ATE546133T1 (de) Orale dosierform mit trisubstituierten glycerin- verbindungen
ES2371825T3 (es) Composiciones para el tratamiento de infecciones vaginales con inflamación crónica.